Study investigates the outcomes of heart transplants from severely obese donors

Heart transplant patients who received hearts from severely obese donors had similar short-term outcomes and long-term survival as patients who received hearts from non-obese donors, according to new research published today in Circulation: Heart Failure, an American Heart Association journal.

The waiting list for a heart transplant in the U.S. is continuously about 3,000 people, and only half of those people receive a donor heart within a year. There is an urgent need to expand the pool of potential heart donors; however, transplant centers are hesitant to accept hearts from obese donors.

In the U.S., almost 40% of the adult population is classified as obese, and nearly 8% have severe obesity, which is defined as a body mass index (BMI) greater than or equal to 40.

As the prevalence of obesity in the U.S. continues to rise, it directly affects the pool of organ donors."

Leora T. Yarboro, MD, Study Lead Author and Associate Professor of Surgery, University of Virginia in Charlottesville, Virginia

"Since the prevalence of severe obesity has increased significantly over the past 15 years, we wanted to investigate the outcomes of recipients of transplant hearts from donors with severe obesity."

The study used the national United Network for Organ Sharing (UNOS) database to analyze the outcomes of 26,000 heart transplants from 2003-2017. Approximately 900, or 3.5%, of the donors had severe obesity. Severely obese donors, a BMI ?40, were more likely to be older and female. In addition:

  • 10% of severely obese donors had diabetes vs. 3% of non-obese donors;
  • 33% of obese donors had hypertension vs. 15% of donors with BMI <40;
  • 67% of heart transplants from severely obese donors were size mismatched (the donor's weight was >130% of the recipient's weight), compared to only 10% of transplants from donors without severe obesity; and
  • transplants from donors with severe obesity increased over time (from 2.2% in 2013 to 5.3% in 2017).

The analysis demonstrated no significant differences in post-transplant outcomes for patients who received a heart from a severely obese donor.

Short-term outcomes, including postoperative stroke, acute rejection of the donor heart, pacemaker need and dialysis requirement, were similar for recipients of hearts from obese and non-obese donors. There was also no difference in one-year survival rates and long-term mortality for patients with transplants from severely obese donors.

"These findings were somewhat surprising because the severely obese donors did tend to have more medical problems, such as diabetes and high blood pressure, than the non-obese donors," Yarboro said.

"This study shows that with careful selection, hearts from obese donors can be used without an increased risk to the recipient. Given the continued increase in obesity in the U.S., this research has the potential to expand the critically low donor pool by increasing the number of donors and improving outcomes for the growing list of patients with end-stage heart failure."

Source:
Journal reference:

Krebs, E. D., et al. (2020) Donor Severe Obesity and Heart Transplant Outcomes. Circulation: Heart Failure. doi.org/10.1161/CIRCHEARTFAILURE.119.006688.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis